Interleukin-1beta enhances the action of bradykinin in rat myenteric neurons through up-regulation of glial B1 receptor expression.
Interleukin (IL)-1beta and tumor necrosis factor alpha (TNFalpha) are released under pathological conditions in the gastrointestinal tract such as inflammatory bowel diseases (IBD). We examined the effects of IL-1beta and TNFalpha on bradykinin (BK) -induced increases in the intracellular Ca(2+) concentration ([Ca(2+)]i) and prostaglandin (PG) E(2) release in neonatal rat myenteric plexus cells. BK evoked a [Ca(2+)]i increase in myenteric neurons and glial cells, both of which were potentiated by treatment with IL-1beta but not TNFalpha. In both cell types, the [Ca(2+)]i responses to BK were abolished by D-Arg(0)[Hyp(3), Thi(5), D-Tic(7), Oic(8)]-BK (HOE140), a B2R antagonist, but not affected by des-Arg(9)-HOE140, a B1R antagonist. After culture with IL-1beta, however, the B1R antagonist suppressed the BK-induced [Ca(2+)]i increase. Only in glial cells did the B1R agonists des-Arg(9)-BK and BK fragment 1-8 evoke a [Ca(2+)]i rise in a dose-dependent manner. Real time RT-PCR and immunocytochemical analyses showed that IL-1beta treatment increased expression of B1R mRNA in myenteric plexus cells and B1R protein in glial cells, respectively. Either indomethacin or an EP1 receptor antagonist suppressed the increased [Ca(2+)]i response to BK invoked by treatment with IL-1beta. IL-1beta treatment increased BK-induced PGE(2) release from cultured myenteric plexus cells. These results suggest that IL-1beta promotes up-regulation of B1R expression in glial cells, resulting in the potentiation of neural responses to BK through the elevation of PGE(2) released from glial cells. The alteration of phenotypes of glial cells may be the cause of the changes in neural function in the enteric nervous system in IBD.
Department of Biomedical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, N18W9, Sapporo 060-0818, Japan.
M
M
Murakami
T
T
Ohta
S
S
Ito
D000818:Animals; D001920:Bradykinin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism / Q000502:physiology; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D015232:Dinoprostone / Q000378:metabolism / Q000502:physiology; D017615:Enteric Nervous System / Q000187:drug effects; D005260:Female; D007150:Immunohistochemistry; D053583:Interleukin-1beta / Q000494:pharmacology*; D008297:Male; D009197:Myenteric Plexus / Q000166:cytology / Q000187:drug effects*; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism; D009474:Neurons / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D020239:Receptor Cross-Talk / Q000187:drug effects; D043783:Receptor, Bradykinin B1 / Q000096:biosynthesis / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
D016207:Cytokines; D053583:Interleukin-1beta; D043783:Receptor, Bradykinin B1; D014409:Tumor Necrosis Factor-alpha; D015232:Dinoprostone; D001920:Bradykinin; D002118:Calcium